GlassScriptPhysician profile
Catherine B Booker
NPI 1316389927
$25,534.41
in general payments reported to CMS, 2019-2025
24 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,058 · 2023: $1,022 · 2024: $5,727 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,195 · Consulting Fee: $2,963 · Education: $672 · Travel and Lodging: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,800.00 |
| Food and Beverage | $6,194.68 |
| Consulting Fee | $2,962.50 |
| Education | $672.39 |
| Travel and Lodging | $275.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $15,190.42 | 2022-2025 | Nemluvio, Aklief |
| Ucb, INC. | $2,580.90 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $2,454.33 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,314.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $844.75 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $555.85 | 2022-2025 | Dupixent |
| Genzyme Corporation | $544.90 | 2021-2025 | |
| Amgen INC. | $384.85 | 2022-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $353.33 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $251.97 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $209.71 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $136.93 | 2022-2024 | Absorica Ld, Winlevi |
| Janssen Scientific Affairs, LLC | $122.76 | 2021 | |
| Leo Pharma INC. | $116.08 | 2023-2025 | Adbry |
| Pfizer INC. | $90.09 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.79 | 2024-2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.22 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $58.23 | 2023-2025 | Zoryve |
| Kyowa Kirin, INC. | $39.98 | 2024 | Poteligeo |
| Vyne Pharmaceuticals INC. | $19.87 | 2021 | |
| Dermavant Sciences, INC. | $17.82 | 2022 | |
| Cipher Pharmaceuticals US LLC | $13.67 | 2025 | Spinosad, Natroba |
| Botanix Sb INC | $13.60 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Booker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.